Triazolothienopyrimidine compound inhibitors of urea transporters and methods of using inhibitors

1. A method for treating a disease or disorder treatable by inhibiting transport of urea in a subject, said method comprising administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of structure (I):

or a single stereoisomer, a mixture of stereoisomers, tautomer or pharmaceutically acceptable salt thereof, wherein,

R 1 is optionally substituted aryl or optionally substituted heteroaryl;

R 2 is —N(R 5 )(R 6 );

R 3 and R 4 are each independently hydrogen, alkyl, halo or haloalkyl;

R 5 is hydrogen or alkyl; and

R 6 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclylalkyl, optionally substituted aralkyl, or optionally substituted heteroarylalkyl; or

R 5 and R 6 , together with the nitrogen atom to which they are attached, form an optionally substituted N-heterocycle, or optionally substituted N-heteroaryl.

2. The method of claim 1 wherein R 1 is optionally substituted phenyl and the compound has a structure of structure (II):

wherein,

n is 0, 1, 2 or 3;

X is an alkylene chain;

R 3 and R 4 are each independently hydrogen, alkyl, halo or haloalkyl;

R 7 is alkyl, halo, haloalkyl, or —OR 9 ;

R 8 is optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl, or —OR 9 ; and

R 9 is hydrogen, alkyl or haloalkyl.

3. The method of claim 2 wherein,

n is 1 or 2;

X is a C 1-5 alkylene chain;

each R 3 and R 4 is independently hydrogen, alkyl, halo or haloalkyl;

R 7 is alkyl, halo, haloalkyl, or —OR 9 ;

R 8 is optionally substituted heteroaryl; and

R 9 is hydrogen, alkyl or haloalkyl.

4. The method of claim 3 wherein,

n is 1 or 2;

X is a C 1-3 alkylene chain;

R 3 and R 4 are each hydrogen;

R 7 is alkyl, halo, haloalkyl, or —OR 9 ;

R 8 is optionally substituted thiophenyl; and

R 9 is hydrogen, alkyl or haloalkyl.

5. The method of claim 4 wherein the compound is

{3-[4-(1,1-difluoro-ethyl)-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine;

thiophen-2-ylmethyl-[3-(4-trifluoromethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine;

thiophen-2-ylmethyl-[3-(4-trifluoromethoxy-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine;

{3-[4-methoxy-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine;

{3-[4-fluoro-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine;

{3-[4-bromo-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine;

{3-[4-chloro-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine;

{3-[3-chloro-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine;

{3-[4-ethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine;

{3-[4-isopropyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine; or

{3-[3,4-dimethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine.

6. The method of claim 3 wherein,

n is 1 or 2;

X is a C 1-3 alkylene chain;

R 3 and R 4 are each hydrogen;

R 7 is alkyl, halo, haloalkyl, or —OR 9 ;

R 8 is optionally substituted furanyl; and

R 9 is hydrogen, alkyl or haloalkyl.

7. The method of claim 6 , wherein the compound is

furan-2-ylmethyl[3-(4-isopropyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine;

furan-2-ylmethyl[3-(4-methyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine;

furan-2-ylmethyl-[3-(3,4-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine;

furan-2-ylmethyl[3-(4-chloro-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine;

furan-2-ylmethyl[3-(4-ethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine; or

furan-2-ylmethyl[3-(2,5-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine.

8. The method of claim 2 wherein,

n is 1 or 2;

X is a C 1-3 alkylene chain;

each R 3 and R 4 is independently hydrogen, alkyl, halo or haloalkyl;

R 7 is alkyl, halo, haloalkyl, or —OR 9 ;

R 8 is —OR 9 ; and

R 9 is hydrogen, alkyl or haloalkyl.

9. The method of claim 8 wherein the compound is

{3-benzenesulfonyl-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-3-methoxypropyl-amine;

{3-[4-methyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-3-(1-methylethoxyl)propyl-amine;

{3-[4-methyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-2-methoxyethyl-amine;

{3-[3,4-dimethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-3-ethoxylpropyl-amine;

{3-[3,4-dimethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-3-(1-methylethoxyl)propyl-amine;

{3-[3,4-dimethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-2-methoxyethyl-amine;

{3-[4-chloro-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-2-methoxyethyl-amine;

{3-[4-chloro-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-3-methoxypropyl-amine;

{3-[4-isopropyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-3-ethoxylpropyl-amine;

{3-[4-isopropyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-2-methoxyethyl-amine;

{3-[4-ethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-2-methoxyethyl-amine;

{3-[4-ethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-3-methoxypropyl-amine;

{3-[4-ethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-3-(1-methylethoxyl)propyl-amine;

{3-[2,5-dimethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-3-ethoxypropyl-amine;

{3-[2,5-dimethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-3-(1-methylethoxyl)propyl-amine;

{3-[2,5-dimethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-2-methoxyethyl-amine; or

{3-[2,5-dimethyl-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-3-methoxypropyl-amine.

10. The method of claim 2 wherein,

n is 1 or 2;

X is a C 1-2 alkylene chain;

each R 3 and R 4 is independently hydrogen, alkyl, halo or haloalkyl;

R 7 is alkyl, halo, haloalkyl, or —OR 9 ;

R 8 is optionally substituted aryl or optionally substituted heterocyclyl; and

R 9 is hydrogen, alkyl or haloalkyl.

11. The method of claim 10 wherein the compound is

[3-(4-isopropyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(4-methoxy-benzyl)-amine;

[3-(4-isopropyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-naphthalen-1-ylmethyl-amine;

[3-(4-methyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(4-methoxy-benzyl)-amine;

[3-(4-methyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(1-phenyl-1-methyl)methyl-amine;

[3-(4-methyl-benz enesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(3-methoxy-benzyl)-amine;

[3-(4-methyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(4-fluoro-benzyl)-amine;

[3-(3,4-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-benzyl-amine;

[3-(3,4-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(2-chloro-benzyl)-amine;

[3-(3,4-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(2-methoxy-benzyl)-amine;

[3-(3,4-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(4-methoxy-benzyl)-amine;

[3-(3,4-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(3-methoxy-benzyl)-amine;

[3-(3,4-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(4-chloro-benzyl)-amine;

[3-(3,4-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(4-fluoro-benzyl)-amine;

[3-(4-ethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-benzyl-amine;

[3-(4-ethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(4-chloro-benzyl)-amine;

[3-(4-ethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(1-phenyl-1-methyl)methyl-amine;

[3-(4-ethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(3-methoxy-benzyl)-amine;

[3-(4-ethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(4-fluoro-benzyl)-amine;

[3-(2,5-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(1-phenyl-1-methyl)methyl-amine;

[3-(2,5-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-(4-fluoro-benzyl)-amine;

[3-(2,5-dimethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-benzyl-amine;

tetrahydrofuran-2-ylmethyl-[3-(4-methyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine;

tetrahydrofuran-2-ylmethyl-[3-(4-isopropyl-benzenesulfonyl)-thienol[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine; or

tetrahydrofuran-2-ylmethyl-[3-(4-ethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine.

12. The method of claim 1 wherein

R 1 is optionally substituted heteroaryl;

R 2 is —N(R 5 )(R 6 );

each R 3 and R 4 is independently hydrogen, alkyl, halo or haloalkyl;

R 5 is hydrogen or alkyl; and

R 6 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclylalkyl, optionally substituted aralkyl, or optionally substituted heteroarylalkyl.

13. The method of claim 12 wherein the compound is [3-(thiophene-2-sulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-thiophen-2-ylmethyl-amine.

14. The method of claim 1 , wherein the disease or disorder treatable by inhibiting transport of urea is selected from (a) refractory edema associated with cirrhosis, nephritic syndrome, acute renal failure, chronic renal insufficiency, hypertension, or congestive heart failure; (b) syndrome of inappropriate antidiuretic hormone secretion (SIADH); (c) azotemia; (e) fluid retention; and (f) abnormal uresis.

15. A compound of structure (III):

or a single stereoisomer, a mixture of stereoisomers, tautomer or pharmaceutically acceptable salt thereof, wherein,

X is an alkylene chain;

Y is —CH═CH 2 —, —CH═N—, S, or O;

each R 3 and R 4 is independently hydrogen, alkyl, halo or haloalkyl;

R 7 is —C(R 10 )(R 11 )—R 12 , —OR 9 or halo;

R 8 is optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl, or —OR 9 ;

R 9 is alkyl or haloalkyl;

R 10 and R 11 are each independently halo or alkyl; and

R 12 is alkyl, halo or haloalkyl,

wherein when Y is —CH═CH 2 — and R 7 is isopropyl at the position para to the linking carbon, R 8 is not furanyl or thiophenyl, and when Y is —CH═CH 2 — and R 7 is Br at the position para to the linking carbon, R 8 is not thiophenyl.

16. The compound of claim 15 wherein,

Y is —CH═CH 2 — or S; and

R 8 is optionally substituted heteroaryl.

17. The compound of claim 16 wherein R 8 is optionally substituted thiophenyl.

18. The compound of claim 17 , wherein the compound is

3-[4-(1,1-difluoro-ethyl)-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine;

thiophen-2-ylmethyl-[3-(4-trifluoromethyl-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine;

thiophen-2-ylmethyl-[3-(4-trifluoromethoxy-benzenesulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-amine;

3-[4-methoxy-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine;

3-[4-fluoro-benzenesulfonyl]-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}-thiophen-2-ylmethyl-amine; or

[3-(thiophene-2-sulfonyl)-thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]-thiophen-2-ylmethyl-amine.

19. A pharmaceutical composition comprising the compound of claim 15 and a pharmaceutically acceptable excipient.

20. A method for treating a disease or disorder treatable by inhibiting transport of urea in a subject, said method comprising administering to the subject the pharmaceutical composition according to claim 19 , wherein the disease or disorder is selected from (a) refractory edema associated with cirrhosis, nephritic syndrome, acute renal failure, chronic renal insufficiency, hypertension, or congestive heart failure; (b) syndrome of inappropriate antidiuretic hormone secretion (SIADH); (c) azotemia; (e) fluid retention; and (f) abnormal uresis.